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Rheumatoid arthritisBackground: Interleukin-6 is a cytokine protein, which causes inflammation, maintains immune home-
ostasis and shows a role in rheumatoid arthritis pathogenesis. IL-6-174G/C promoter polymorphism
may have a role in susceptibility to RA.
Aim of the work: To evaluate the clinical significance of serum levels of IL-6 and its -174G/C promoter
polymorphism in RA patients in comparison with the controls.
Patients and methods: This study enrolled 25 non hepatitis C virus RA patients versus 25 age and gender
matched controls. Demographic, clinical and laboratory data were prospectively evaluated. Serum IL-6
level and promoter (-174G/C) genotype were determined.
Results: Serum IL-6 levels was significantly higher in RA patients compared to control subjects (p = .001),
especially those with CC promoter polymorphism. There was a significant correlation between IL and 6
level and duration of morning stiffness, disease activity, hemoglobin concentration and ESR level.
15/25 patients had (-174G/G) gene promoter polymorphism, 8/25 were GC and 2/25 were CC. All controls
were GG. There was significant association between gene polymorphism and age at disease onset (p =
.0172), which was older in those with GG genotype (38.5 ± 10.25 years) than those with CC (33.5 ± 0.7
1 years) and younger in GC genotypes (27.9 ± 7.9 years). None of the other clinical, laboratory or radio-
logical parameters would predict the IL-6 promoter polymorphism.
Conclusion: Serum IL-6 levels and -174G/C promoter polymorphism were higher in RA patients than in
healthy controls. The positive correlation of IL-6 level with the DAS28 and duration of morning stiffness
may confirm its’ increased involvement in the pathogenesis of RA and may point to the need for consid-
ering of anti-IL-6 agents in their management plan. The negative correlation of IL-6 level with the hemo-
globin level may confirm IL-6 play a significant role in anemia of RA.
 2017 Ain Shams University. Production and hosting by Elsevier B.V. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction Rheumatoid arthritis (RA) is a chronic, systemic inflammatoryAutoimmune diseases are major causes of morbidity and mor-
tality in the industrialized world. Autoimmunity develops after
breaking self-tolerance of the immune system [1].disease affecting joints mainly. Although it is primarily considered
a disease of the joints, abnormal systemic immune responses are
evident and can cause a variety of extra articular manifestations
[2]. RA has been known as a multifactorial disease sustained by
environmental and genetic factors. These factors seem to be neces-
sary although not sufficient in disease development. However,
these factors can be responsible for different clinical pictures and
response to therapy. Several genes have been incriminated so far
in the pathogenesis of RA. Elevated levels of pro-inflammatory
cytokines are key features in patients with RA [3].
Abnormalities in cytokines, their receptors, and their signaling
pathways are involved in a wide variety of diseases. Solid evi-
dences have implicated IL-6 in the pathogenesis of RA [4]. IL-6
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temic features of inflammation [5]. Its serum concentration is sig-
nificantly elevated in RA patients and decreases with medical
treatment proposing its role in the pathogenesis of RA [6]. Further-
more, its-174 promoter polymorphism is associated with disease
susceptibility and activity and also constitutes a genetic risk factor
[7,8]. Single nucleotide polymorphisms (SNPs) in IL-6 genes -174G/
C have been associated with RA susceptibility and radiographic
severity of bone-erosive damage [6]. The ‘‘anti-cytokine medicine”
is a rapidly growing field that may dramatically affect disease man-
agement. Tocilizumab, a recombinant humanized monoclonal IgG1
antihuman interleukin 6-receptor antibody is now indicated for
the treatment of adults with RA who have failed to respond to at
least one synthetic disease-modifying anti-rheumatic drug or TNFa
antagonist [9]. The discovery of new genes associated with the dis-
ease may play a crucial role in understanding the development,
progression and outcome of RA [3].
Hepatitis C Virus (HCV) still affects a substantial proportion of the
Egyptian population. It is estimated that in the 15- to 59-year age
groups, the prevalence of HCV antibody was 10.0% and that HCV
RNA was 7.0%. In children, 1–14 years old, the prevalence of HCV
antibody and HCV RNA were 0.4% and 0.2% respectively. Approxi-
mately, 3.7 million persons have chronic HCV infection in the age
group 15–59 in 2015[10]. HCV is a hepatotropic lymphotropic virus.
Lymphotropism and chronic stimulation of the immune system by
several viral proteins may be responsible for non-organ specific
autoantibody production as rheumatoid factor (RF) and cryoglobu-
lins [11]. Elevated levels of interleukin (IL-6) levels are observed in
rheumatoid and HCV-related arthritis. However, this increase is
not related to HCV viremia [12]. Anti-cyclic citrullinated peptide
(ACCP) positivity is considered specific for a differential diagnosis
of arthritis in patients infected with HCV and is more significant
for rheumatoid arthritis than the other causes [12]. Rheumatologic
extrahepatic manifestations are observed in many HCV-infected
patients. These include arthralgia (23%), paresthesia (17%), myalgia
(15%), pruritus (15%), and sicca syndrome (11%) [13].2. Aim of the work
To evaluate the clinical significance of serum levels of IL-6 and
its -174G/C promoter polymorphism in non HCV RA patients in
comparison with the controls.3. Subjects & methods
3.1. Study population
Twenty-five RA patients diagnosed according to the 2010 ACR/
EULAR RA classification criteria [14] were consecutively recruited
from the Rheumatology outpatient clinic and department of Cairo
University Hospitals versus 25 age and gender matched healthy
controls. Full history taking and thorough clinical examination
were performed for all the patients. Laboratory investigations in
the form of complete blood count (CBC), erythrocyte sedimenta-
tion rate (ESR), rheumatoid factor (RF) and/or ACCP and plain X-
rays for the affected joints were assessed. Disease activity score
(DAS-28) was calculated [15]. Informed consent was taken from
each patient. The work has been carried out in accordance with
The Code of Ethics of The World Medical Association of Helsinki
for experiments in humans.
3.1.1. Patient exclusion criteria
Patient with HCV were excluded as HCV can cause arthritis
which may be misdiagnosed as RA. Also hepatitis may increase
the level of IL-6. All patients were negative for HCV antibodies.3.2. Methods
3.2.1. Determination of serum IL-6 level
Serum IL-6 was assayed using Human IL-6 ELISA kit (BOSTER
BIOLOGICAL TECHNOLOGY Co., Ltd. 3942 B Valley Ave, Pleasanton,
California America, 94566).
3.2.2. Determination of IL-6 gene (-174G/C) promoter polymorphism
Promoter region polymorphism of IL-6 gene (-174G/C) was
determined by polymerase chain reaction-restriction fragment
length polymorphism (PCR-RFLP) technique.
DNA isolation and IL-6 genotyping: genomic DNA was isolated
from white blood cells using (ZYMO RESEARCH CORP) whole Blood
Genomic DNA Extraction Kit.
Enzymatic amplification was performed by PCR using Master
Taq polymerase enzyme (Bio-25044mytaq red mix Meridian Bio-
science Asia Pte Ltd, SINGAPORE) and Biometra T personal thermal
cycler. Amplification of the promoter region (-174G/C) of the IL-6
gene was done as proposed by Pola et al. [16] using 2 primers pur-
chased from Operon Biotechnologies (GmbH/Biocampus, Ger-
many). Forward Primer: 50-GCC TCA ATG ACG ACC TAA GC-30,
and Reverse Primer: 50-TCA TGG GAA AAT CCC ACA TT-30.
The PCR reaction mixture (50 ll) contained 25 ll MyTaqTM Red
Mix2x (MyTaq Red Mix, 2x is a pre-mixed solution containing
Thermus aquiticus (Taq) DNA polymerase, PCR buffer, dNTP, gel
loading dyes and fluorescence dye), 1 ll of each primer (25 pmol),
5 ll of genomic DNA and 18 ll sterilized nuclease-free water. The
reaction was carried out with the following cycles: 95 C for 5 min;
35 cycles of 30 s denaturation at 95 C, 30 s annealing at 63 C and
30 s extension at 72 C and a 10-min final extension at 72 C after
completion of the cycles.
Then amplified products were digested with 5 units of Fast
Digest NLaIII restriction enzyme (Time-SaverTM Qualified (New Eng-
land biolabsinc, USA). The digested products were detected in 2%
agarose gel containing ethidium bromide by performing elec-
trophoresis on the gel electrophoresis apparatus and were visual-
ized by UV transillumination. A single band at 163 bp identified
GG homozygous individuals, two bands at 111 and 52 bp identified
CC homozygous individuals, and three bands at 163, 111 and 52 bp
identified a GC heterozygote.
3.3. Statistical analysis
Data were coded and entered using the statistical package SPSS
version 23. Data were summarized using mean, standard deviation,
median, minimum and maximum in quantitative data and using
frequency (count) and relative frequency (percentage) for categor-
ical data. Comparisons between quantitative variables were done
using the non-parametric Kruskal-Wallis and Mann-Whitney tests.
For comparing categorical data, Chi square test was performed.
Exact test was used instead when the expected frequency is less
than 5. Correlations between quantitative variables were done
using Spearman correlation coefficient). P-values less than .05 were
considered as statistically significant.4. Results
Fifty subjects were enrolled in this study; 25 RA (23 females and
2 males) and 25 age and sex matched healthy controls with a mean
age of 48.04 ± 14.54 years (23 females and 2 male). The clinical fea-
tures, laboratory results, radiological findings and medications
used at the time of the study are shown in Table 1 and Table 2.
The mean IL-6 level was significantly higher in the patients
group (50.59 ± 43.33 pg/ml) compared with the control group
(13.32 ± 7.67 pg/ml) (p < .001).
Table 1
Demographic, clinical and laboratory features of RA patients.
Mean Standard deviation Median Minimum Maximum
Age (years) 43.96 12.14 42.00 25.00 66.00
Onset (years) 8.96 8.64 6.00 2.00 31.00
Platelets (103/ml) 260.72 81.64 237.00 163.00 420.00
TLC* (103/ml) 7.24 2.32 7.50 3.40 12.40
Hemoglobin (g/dl) 11.45 1.59 11.70 7.90 15.20
ESR** (mm/1st hr) 48.00 26.47 46.00 12.00 105.00
Swollen joint 4.24 6.02 1.00 .00 22.00
Tender joint 6.28 8.22 3.00 .00 27.00
DAS28*** 4.11 1.49 3.66 1.98 7.16
Morning stiffness (min.) 32.40 68.36 .00 .00 240.00
* TLC: total leukocyte count.
** ESR: erythrocyte sedimentation rate.
*** DAS28: disease activities score for 28 joints.
Table 2
Clinical, laboratory and radiological features of RA patients.
Count %
Rheumatoid factor Positive 20 80.0%
Negative 5 20.0%




X-RAY erosion Yes 13 52.0%
No 12 48.0%
Subcutaneous nodule Yes 4 16.0%
No 21 84.0%
Methotrexate Yes 23 92.0%
No 2 8.0%
Leflunomide Yes 5 20.0%
No 20 80.0%
Chloroquine Yes 10 40.0%
No 15 60.0%
Prednisolone Yes 13 52.0%
No 12 48.0%
* DAS28: disease activities score for 28 joints.
Fig. 1. Correlation between patients’ IL-6 serum level and DAS28.
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patients group & the control group regarding IL-6 (-174G/C) pro-
moter polymorphism types (p = .001). Fifteen patients (60%) were
GG IL-6 (-174G/C) genotype, 8 (32%) were GC and 2 (81%) were
CC genotype. However, all the 25 controls subjects were GG
genotype.
Serum IL-6 was higher in patients with CC genotype (76 ± 62.
23 pg/ml) compared to those with GG genotype (48.56 ± 48.01 p
g/ml) and GC genotype (48.05 ± 33.24 pg/ml), yet no statistically
significant difference was observed (p = .716).
There was a statistically significant difference between gene
polymorphism and age at disease onset (p = .0172). Older ages of
disease onset were those harboring GG genotype (38.5 ± 10.25 ye
ars), followed by CC genotype (33.5 ± 0.71 years) and finally those
with GC genotype (27.9 ± 7.9) years.
However, there was no correlation between IL and 6 serum
level with the age at disease onset (r = 0.1678, p = .423).
Bone erosions revealed by X-ray were detected in all patients
with CC genotype 2 (100%) compared to 7 patients (46%) with
GG allele and 4 patients (50%) with GC allele. However, of no sig-
nificance (p = .580). While no significant correlation was found
between IL and 6 level with bone erosion.
There was a positive correlation between IL and 6 level with
DAS28 (r = 0.692, p < .001) (Fig. 1), number of swollen joints (r =
0.68, p = .003) and number of tender joints (r = 0.677, p < .001).However the difference in DAS28, number of swollen joints and
number of tender joints among the different alleles were statisti-
cally insignificant (p = .943), (p = .979) and (p = .826) respectively.
Regarding the correlation between IL and 6 (174G/C) promoter
polymorphism with the duration of morning stiffness, although
not statistically significant, yet those with GG genotype had a
higher duration of morning stiffness (42 min) compared to the
GC genotype (19 min) and CC genotype (7 min) (p = .766). However
there was a significant correlation between IL and 6 level and dura-
tion of morning stiffness (r = 0.607, p = .001) (Fig. 2) Also when
analyzing IL-6 (174G/C) promoter polymorphism with appearance
of subcutaneous nodules (SC) between the different alleles,
although not statistically significant, yet 50% patients with CC
allele were shown to have subcutaneous nodules in comparison
to 6.7% patients with GG allele and 25% patients with GC allele
(p = .167). Moreover there was no significant correlation between
serum IL-6 level and the appearance of subcutaneous nodules.
As for various laboratory variables in RA patients, there was a
positive correlation between IL and 6 level with ESR (r = 0.402,
p = .047). While a negative correlation was found with hemoglobin
level (HB) (r = 0.582, p = .002). However, no correlation was found
between IL and 6 (174G/C) promoter polymorphism with either
ESR or HB.
No significant association was found between IL and 6 or its
(-174G/C) promoter polymorphism with platelet count, total
leukocyte count, RF or treatment with methotrexate, Chloroquine
and/or Prednisolone. None of the studied clinical and laboratory
parameters would predict the IL-6 promoter polymorphism.
Fig. 2. Correlation between patients’ IL-6 serum level and duration of morning stiffness.
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In the current study, the mean serum IL-6 level which was sig-
nificantly higher in 25 RA patients (50.59 ± 43.44 pg/ml) compared
to 25 sex and age matched control subjects (13.32 ± 7.67 pg/ml)
(p = .001). In agreement with our study, Gaber et al. (2013)
observed that the mean IL-6 level for 37 Egyptian RA patients (58.
45 ± 147.09 pg/ml) was significantly higher than its level in the
control group (10 subjects) (7.71 ± 8.59 pg/ml) (p = .044) [17]. This
is in concordance with Chung et al. (2011) who found that in 40
Korean patients IL-6 serum level was significantly higher than their
40 matched controls [6]. Similarly, higher levels of IL-6 were
present in serum, synovial tissue and synovial fluid from patients
with RA compared to those with non-inflammatory arthritis [4].
Malaguarnera et al. (1996) showed that serum IL-6 levels were
more elevated in patients with liver disease than in healthy sub-
jects, and that IL-6 levels increased as the histological activity of
the liver disease progressed [18].
HCV-related arthritis can present with joint involvement symp-
toms similar to RA. Thus, clinically, it may be almost impossible to
distinguish HCV-related arthritis from RA [19]. Rheumatoid factor
(RF) is antibody produced by the immune system that can attack
healthy tissue in the body. RF positivity is approximately 70–80%
in patients with RA, and in HCV-related arthritis, this positivity
ranges between 54% and 82% [20]. Moreover, RF is nonspecific
and may be present in several diseases. On the other hand, anti-
citrullinated protein antibodies (ACPA) are autoantibodies (anti-
bodies to an individual’s own proteins) that are directed against
peptides and proteins that are citrullinated. ACPA are more specific
for RA (96–98%) and are present in approximately 75–80% patients
with RA. However, it has been shown that ACPA are present in 4.5%
to 7% of patients with HCV-related arthritis [20]. For that reason
HCV rheumatoid arthritis patients were excluded from our study.
In the present study there was a highly statistically significant
difference between patient group & control group regarding IL-6
(-174G/C) promoter polymorphism types. For the patient group
60% were shown to have GG IL-6 (-174G/C) genotype, 32% with GC
genotypeand8%withCCgenotypewhile100%of the control showed
GG genotype (p = .001). In agreementwith our results another study
on37EgyptianRApatients reported that 64.86%of the patientswere
shown to have GG allele, 29.73% with GC and 5.41% with CC, while
90%of the control showedGGgenotypewith one individual present-
ing with GC [17]. Similarly, another study conducted on Chinesepeople found significant difference in the genotypes resulting from
IL to 6 (-174G/C) gene promoter polymorphismbetweenRApatients
andhealthy subjects [21]. On theotherhand, another study included
98patientswithRA inPoland reported that among the studiedgroup
53 (54.1%) were heterozygous GC, 26 (26.5%) were homozygous GG
and homozygous CC genotypewas observed in 19 (19.4%) cases. The
same study found that among the studied group of control subjects
(105) the genotypes GC, GG and CC were found in 58 (55.2%), 25
(23.8%) and 22 (21.0%) subjects, respectively. As shown, the study
concluded that the distribution of IL-6 genotypes in RA patients
did not differ significantly from that in the control group [7]. Simi-
larly, in Spain Palomino-Morales et al. (2009) conducted their study
on 311 RA patients and 226matched controls. They found no signif-
icant differences in the IL-6 -174 allele and its genotype frequencies
betweenRApatients and the control group [22]. Details they showed
that GC allele ranked first followed by GG and finally CC in the
patient group,while in the control groupGG showed the highest fre-
quency followed by GC and CC. However, Marinou et al. (2007) in
United Kingdom reported that the frequency of the CC IL-6
(-174G/C) gene promoter polymorphism was lower in RA patients
than in the controls [7]. A meta-analysis study found that IL-6-
174G/C polymorphismmay confer susceptibility to RA in Europeans
[23]. While another meta-analysis study explained this divergence
by the different genetic backgrounds. For instance, the -174C allele
and its relatedgenotypeswereexceedingly lower inAsians andEast-
ern Chinese than in Europeans and other regions, respectively. Actu-
ally, it is nowbelieved that one gene variantmayplay a different role
in RA risk across different populations and regions [24].
In the present study, there was no statistically significant corre-
lation between IL and 6 serum levels and IL-6 (-174G/C) promoter
polymorphism types (p = .716) although the IL-6 serum level was
higher in those with CC genotype compared to those with GG
and GC genotype. Nevertheless, Gaber et al. (2013) found signifi-
cant correlation between IL and 6 serum level and IL-6 (-174G/C)
promoter polymorphism types which was significantly higher in
CC genotype (546 ± 343.65 pg/ml) compared to those with GC
genotype (69.97 ± 113.23 pg/ml), (p < .0001) and GG genotype
(12.54 ± 14.82 pg/ml). Contrarily in Spanish population, -174 CC
genotype was associated with a reduced IL-6 promoter strength
of expression and IL-6 serum levels were lower in subjects with
the CC genotype compared with GC or GG subjects [25]. Others sta-
ted that no definite association between gene polymorphisms and
IL-6 serum level was noticed [26].
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the clinical manifestations and laboratory findings of RA patients:
we found that there was a significant correlation between IL and
6 level and duration of morning stiffness, number of swollen joints,
number of tender joints, DAS 28, ESR and hemoglobin level p val-
ues .001, .003, .001, .001, .047 and .002 respectively. In agreement
with the present study a study in Netherlands, found that among
51 RA patients there was a significant correlation between IL and
6 level with ESR (r = 0.744, p < .001), hemoglobin level (r = 0.31
1, p < .05) and duration of morning stiffness (p < .05). Moreover,
IL-6 level in RA patients is correlated positively with disease activ-
ity (p < .05) [27]. Previous studies have also found a significant cor-
relation between serum IL-6 activity and the serum levels of
various acute phase reactants. The pro-inflammatory role of the
IL6 system in established RA has been highlighted by the use of
anti-sIL-6R antibodies; however, a protective effect of IL-6 on the
risk of developing RA has been suggested [7]. On the other hand
Gaber et al. (2013) found no significant relationship between IL
and 6 levels and DAS28 (p = .5) [17]. Another study by Chung
et al. (2011) found a significantly positive correlation of serum con-
centrations of IL-6 with CRP levels (r = 0.45, p = .007), but not with
DAS28 (r = 0.28, p = .102); However, After eight weeks of medical
treatment in patients with high disease activity, a decrease in
DAS28 was associated with a significant decrease in the serum
concentrations of IL-6 and IL-11 [6].
In the present study, there was positive correlation of the serum
IL-6 level with the duration of morning stiffness; those with GG
genotype had a higher duration (42 min) than GC genotype (19
min) and CC genotype (7 min). Another study on patients with GG
genotype found a significant correlation between IL and 6 level
and duration of morning stiffness (r = 0.44, p = .033) [17]. This con-
ditionmaybe attributed to the limited ability of endogenous cortisol
releasedduring the night to counter the high levels of Il-6 [28]. Some
RA patients in remission still experience prolonged duration of
morning stiffness and thus it remains an importantmarker of active
disease that should continue to be monitored [29]. Major improve-
ment in duration of morning stiffness was observed in RA patients
treated by IL-6-receptor antagonist tocilizumab [29].
In the present study, there was no significant correlation of the
serum IL-6 level with platelet count (r = 0.172, p = .411). Also Gaber
et al. (2013) found no significant correlation of the serum IL-6 level
with platelet count [17]. Contrarily, a study by Van Leeuwen et al.
(1995) observed a significant correlation between IL and 6 level
and platelet count (r = 0.744, p < .001) [27]. Although thrombopoi-
etin acts as an acute phase protein but is not exclusively responsi-
ble for thrombocytosis of inflammatory disorders, the positive
correlation of IL-6 serum level with the platelet count makes it a
recognized reliable candidate and as a cooperating factor [30].
As for rheumatoid factor in the present study, we found no sig-
nificant differences between Il and 6 serum level (p = .272) or pro-
moter genes (p = 1) with RF-positive and negative patients
Moreover, the disease activity did not differ between RF-positive
and negative patients. In agreement with Burmester et al. (2011)
in their study on Korean patients [31].
In our study, we found IL-6 level non significantly correlated
with the age at disease onset (r = 0.168, p = .423). However, we
found association between gene polymorphism and age at disease
onset (p = .0172). The age at disease onset was older in those with
GG genotype (38.5 ± 10.25 years), in comparison to those with CC
genotype (33.5 ± 0.71 years) and those with GC genotype (27.9 ±
7.9 years). However, Gaber et al. (2013) found that IL-6 level was
inversely correlated with the age at disease onset (r = 0.34, p =
.037) and there was tendency for association between gene poly-
morphism and age at disease onset (r = 0.32, p = .057) [17].
In the present study, when comparing IL-6 (-174G/C) promoter
polymorphism types with patients’ radiological findings and treat-ment data; no statistically significant difference regarding joint or
bone erosion by X-ray was found; however, all patients with CC
genotype had bone erosion which was present in only 50% in the
other genotypes. In agreement with the results of Gaber et al.
(2013) who utilized the modified Larsen score which detect bone
erosion found that it tended to be higher in those with CC geno-
type, but the difference was not significant [17]. Supporting our
results Ceccarelli et al. (2011) found that bone erosive damage in
77 Italian RA patients was significantly correlated with those with
CC genotype (p = .007) [32]. Of particular relevance to RA, IL-6
induces osteoclast differentiation, contributing to joint destruction,
bone resorption and osteoporosis [33].
In our study there was no statistical association between nei-
ther IL-6 serum level nor IL-6 -174G/C promoter polymorphism
and treatment with methotrexate (p = .06, p = 1), Chloroquine
(p = .285, p = 1) and/or Prednisolone (p = .936, p = .494). Similarly,
Gaber et al. (2013) found no statistically significant association
between IL and 6 serum level or its -174G/C promoter polymor-
phism and treatment with methotrexate, Chloroquine and/or Pred-
nisolone [17]. IL-6 is considered the most abundant cytokine in the
joints and serum of RA patients and its level correlates with disease
activity [33]. Pawlik et al. (2005) suggested that IL-6 (-174) pro-
moter polymorphism may be a genetic risk factor determining
the effectiveness of RA treatment with methotrexate and glucocor-
ticoids as the incidence of remission after therapy was significantly
lower in patients with GG genotype compared with GC and CC
genotypes [7]. Targeting IL-6R with a humanized anti IL-6R mono-
clonal antibody (tocilizumab) successfully controls local and sys-
temic inflammatory manifestations and prevents cartilage and
bone destruction [5]. Impairment of physical function and
health-related quality of life, as well as fatigue, were all improved
more with tocilizumab than with placebo, reflecting substantial
functional benefits for the patients [33].
In the present study, when comparing IL-6 (-174G/C) promoter
polymorphism types with patients’ clinical and laboratory data;
there was no statistically significant difference regarding the onset
of disease (p = .237), number of swollen joint (p = .979), number of
tender joints (p = .826), DAS28 (p = .943), subcutaneous nodule
(p = .167), platelet count (p = .930), TLC (p = .703), hemoglobin
level (p = .3) and ESR (p = .974). Similarly, many other authors
reported no difference in clinical and laboratory parameters,
regarding the duration, extra-articular manifestations, DAS28,
and laboratory parameters (ESR, HB level and platelet count) in
the different IL-6 -174 genotypes[17,25,26]. However, Pawlik
et al. (2005) found that, in patients with a GG genotype, the active
form of RA was more frequently diagnosed compared with CC and
GC patients. Moreover, in GG genotype carriers the parameters of
DAS28, ESR, and number of swollen and tender joints were signif-
icantly increased [7].6. Conclusions
Serum IL-6 levels and its-174G/C promoter polymorphism were
higher in Egyptian RA patients than in Egyptian healthy controls.
None of the studied parameters would predict the promoter poly-
morphism except age at disease onset. The data from the present
study indicate that a rare variant (C allele) in IL-6-174G/C pro-
moter polymorphism may play a significant role in genetic suscep-
tibility for RA in the Egyptian population. The positive correlation
of IL-6 with the DAS28 and duration of morning stiffness may con-
firm its increased involvement in the pathogenesis of RA and may
point to the need for considering of anti-IL-6 agents in the manage-
ment plan. Further studies with larger sample size are required to
delineate the differences in genetic susceptibility to RA in various
ancestral groups.
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